Diffuse Large B Cell Lymphoma

P1/2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Jan 2027

P=N/A, N=100, Not yet recruiting, International Extranodal Lymphoma Study Group (IELSG) | Initiation date: Apr 2026 --> Sep 2026

These cases underscore a rare clinical entity that differs pathophysiologically from pyothorax-associated lymphoma (PAL) or primary effusion lymphoma (PEL). They highlight the postpneumonectomy cavity as a rare but potentially permissive microenvironment for large B-cell lymphomagenesis and underscore the biological heterogeneity of these presentations.

Kaplan-Meier analysis underscored the superior discriminatory capacity of the immune index in assessing the prognosis across various risk groups. The proposed immune index is a useful tool to predict the prognosis of DLBCL patients treated with R-CHOP immunochemotherapy in this study.

P=N/A, N=85, Recruiting, University Hospital, Montpellier | Trial completion date: May 2026 --> Feb 2027 | Trial primary completion date: May 2026 --> Feb 2027

P1, N=10, Recruiting, The University of Texas Health Science Center at San Antonio | Trial completion date: Jul 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Oct 2026

Although TP53 mutations are associated with poor prognosis in patients treated with chemotherapy, their adverse prognostic impact appears to be attenuated in the context of CAR-T cell therapy. These findings suggest that CAR-T therapy may partially mitigate the negative impact of TP53 alterations.

Primary CNS lymphoma presenting as an isolated third ventricular lesion is extremely rare and often radiologically mimics other intraventricular tumours. Histopathological confirmation is mandatory before initiating oncological therapy. Surgical intervention should be limited to biopsy if lymphoma is highly suspected, with cerebrospinal fluid diversion when required. Awareness of this rare tumour is essential to avoid unnecessary aggressive resections and to facilitate early initiation of chemotherapy.

In contrast, high levels of β2-microglobulin may help identify a sub-group of high-risk patients. This biomarker may be helpful in refining treatment plans or designing future clinical trials.

The patient received 4 cycles of an attenuated R-THP-COP regimen (rituximab, pirarubicin [tetrahydropyranyl adriamycin, THP, substituted for doxorubicin to reduce cardiotoxicity], cyclophosphamide, vincristine and prednisone). In this single elderly patient, an attenuated R-THP-COP regimen was well tolerated and produced a sustained complete clinical response, suggesting that an individualised, biopsy-guided, chemotherapy-based approach may be a reasonable option for similarly localised disease in elderly patients; this observation, however, requires confirmation in larger series. This case enriches the clinical data of this rare disease and provides a reference for clinical diagnosis and treatment.

P2, N=69, Recruiting, Rong Tao | Not yet recruiting --> Recruiting

P=N/A, N=500, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting